Puberty and its disorders

Pediatric Endocrinology, Fifth Edition: Volume 2 Growth, Adrenal, Sexual, Thyroid, Calcium, and Fluid Balance Disorders

Volumn , Issue , 2006, Pages 273-303

  Lee, Peter A ^a,b   Houk, Christopher P ^c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057356915     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (111)

1. Sisk CL, Foster DL. The neural basis of puberty and adolescence. Nat Neurosci 2004; 7:1040-1047.
2. Crofton PM, Evans AE, Groome NP, Taylor MR, Holland CV, Kelnar CJ. Dimeric inhibins in girls from birth to adulthood: relationship with age, pubertal stage, FSH and oestradiol. Clin Endocrinol (Oxf) 2002; 56:223-230.
3. Seminara S, Messager S, Chatzidaki E, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349:1614-1627.
4. Messager S, Chatzidaki EE, Ma D, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci U S A 2005; 102:1761-1766.
5. Plant TM, Ramaswamy S, Dipietro MJ. Repetative activation of hypothalamic GPR54 with intravenous pulses of kisspeptin in the juvenile monkey (Macaca mulatta) elicits a sustained train of GnRH discharges. Endocrinology 2006; 147:1007-1013.
6. Semple RK, Achermann JC, Ellery J, et al. Two novel missense mutations in a g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90:1849-1855.
7. Dode C, Hardelin JP. Kallmann syndrome: fibroblast growth factor signaling insufficiency? J Mol Med 2004; 82:725-734.
8. Sun SS, Schubert CM, Chumlea WC, et al. National estimates of the timing of sexual maturation and racial differences among US children. Pediatrics 2002; 110:911-919.
9. Sun SS, Schubert CM, Liang R, et al. Is sexual maturity occurring earlier among U.S. children? J Adol Health 2005; 37:345.
10. Chumlea WC, Shubert CM, Roche AF, et al. Age at menarche and racial comparisons in US girls. Pediatrics 2003; 111:110-113.
11. Freedman DS, Kahn LK, Serdula MK, Dietz WH, Srinivasan SR, Berenson GS. Relation of age at menarche to race, time period, and anthropometric dimensions: The Bogalusa Heart Study. Pediatrics 2002; 110:e43.
12. Biro FM, Lucky AW, Huster GA, Morrison JA. Pubertal staging in boys. J Pediatr 1995; 127:100-102.
13. Andersson AM, Juul A, Petersen JH, Muller J, Groome NP, Skakkebaek NE. Serum inhibin B in healthy pubertal and adolescent boys: relation to age, stage of puberty, and follicle-stimulating hormone, luteinizing hormone, testosterone, and estradiol levels. J Clin Endocrinol Metab 1997; 82:3976-3981.
14. Crofton PM, Evans AE, Wallace AM, Groome NP, Kelnar CJ. Nocturnal secretory dynamics of inhibin B and testosterone in pre-and peripubertal boys. J Clin Endocrinol Metab 2004; 89:867-874.
15. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab 2004; 89:3644-3650.
16. Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R. Sexual precocity in boys: Accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001; 86:4127-4132.
17. Lazar L, Kauli R, PertzelanA, Phillip M.Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002; 87:2090-2094.
18. Virdis R, Street M, Zampoli M, et al. Precocious puberty in girls adopted from developing countries. Arch Dis Child 1998; 78:152-154.
19. Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C, Brauner R. Central precocious puberty: clinical and laboratory features. Clin Endocrinol (Oxf) 2001; 54:289-294.
20. Debeneix C, Bourgeois M, Trivin C, Sainte-Rose C, Brauner R. Hypothalamic hamartoma: comparison of clinical presentation and magnetic resonance images. Horm Res 2001; 56:12-18.
21. Brandberg G, Raininko R, Eeg-Olofsson O. Hypothalamic hamartoma with gelastic seizures in Swedish children and adolescents. Eur J Paediatr Neurol 2004; 8:35-44.
22. Freeman JL, Coleman LT, Wellard RM, et al. MR imaging and spectroscopic study of epileptogenic hypothalamic hamartomas: analysis of 72 cases. AJNR Am J Neuroradiol 2004; 25:450-462.
23. Buzi F, Pilotta A, Dordoni D, Lombardi A, Zaglio S, Adlard P. Pelvic ultrasonography in normal girls and girls with pubertal precocity. Acta Paediatr 1998; 87:1138-1145.
24. Brito VN, Batista MC, Borges MF, et al. Diagnostic value of flourometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab 1999; 84:3539-3544.
25. Chalumeau M, Chemaitilly W, Trivin C, Adan L, Breart G, Brauner R. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics 2002; 109:139-141.
26. Rivarola M, Belgorosky A, Mendilaharzu H, Vidal G. Precocious puberty in children with tumours of the suprasellar and pineal areas: organic central precocious puberty. Acta Paediatr 2001; 90:751-756.
27. Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123:509-518.
28. Anasti JN, Flack MR, Froelich J, Nelson LM, Nisula BC. A potential novel mechanism for precocious puberty in juvenile hypothroidism. J Clin Endocrinol Metab 1995; 80: 276-279.
29. Choong CS, Fuller PJ, Chu S, et al. Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12-month-old infant. J Clin Endocrinol Metab 2002; 87:49-56.
30. Ghazi AA, Mofid D, Rahimi F, Sadeghii-Nejad A. Cortisol and estradiol secretion by a benign virilizing adrenocortical tumor in a prepubertal girl. J Pediatr Endocrinol Metab 2004; 17:235-238.
31. Muensterer OJ, Till H, Schwarz HP, Joppich I. Testosterone-producing adrenocortical neoplasm in a 6-year-old boy. Eur J Pediatr Surg 2001; 11:354-357.
32. Phornphutkul C, Okubo T, Wu K, et al. Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty. J Clin Endocrinol Metab 2001; 86:649-652.
33. Richter-Unruh A, Wessels HT, Menken U, et al. Male LHindependent sexual precocity in a 3.5-year-old boy caused by a somatic activating mutation of the LH receptor in a Leydig cell tumor. J Clin Endocrinol Metab 2002; 87:1052-1056.
34. Li ST, Lozano P, Grossman DC, Graham E. Hormone-containing hair product use in prepubertal children. Arch Pediatr Adolesc Med 2002; 156:85-86.
35. Yu YM, Punyasavatsu N, Elder D, D’Ercole AJ. Sexual development in a two-year-old boy induced by topical exposure to testosterone. Pediatrics 1999; 104:1-2.
36. Kunz GJ, Klein KO, Clemons RD, Gottschalk ME, Jones SKL. Virilization of young children after topical androgen use by their parents. Pediatrics 2004; 114:282-284.
37. Cohen HL, Eisenberg P, Mandel F, Haller JO. Ovarian cysts are common in premenarchal girls: A sonographic study of 101 children 2-12 years old. Am J Roentgenol 1992; 159:89-91.
38. Shenker A, Laue L, Kosugi S, Merendion JJ Jr., Minegish T, Cutler GB Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993; 365:652-654.
39. Latronico AC, Lins TS, Brito VN, Arnhold IJ, Mendonca BB. The effect of distinct activating mutations of the luteinizing hormone receptor gene on the pituitarygonadal axis in both sexes. Clin Endocrinol (Oxf) 2000; 53:609-613.
40. Leschek EW, Chan WY, Diamond DA. Nodular Leydig cell hyperplasia in a boy with familial male-limited precocious puberty. J Pediatr 2001; 138:949-951.
41. Bertelloni S, Baroncelli GI, Lala R, et al. Long-term outcome of male-limited gonadotropin independent precocious puberty. Horm Res 1997; 48:235-239.
42. Soriano-Guillen L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab 2005; 90:147-151.
43. Eugster EA. Aromatase inhibitors in precocious puberty: rationale and experience to date. Treat Endocrinol 2004; 3:141-151.
44. Reiter EO, Norjavaara E. Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev 2005; 3:77-86.
45. Domenice S, Latronica AC, Brito VN, Amhold IJ, Kok F, Mendonca BB. Adrenocorticopin-dependent precocious puberty of testicular origin in a boy with X-linked adrenal hypoplasia congenital to a novel mutation in the DAXI Gene. J Clin Endocrinol Metab 2001; 86:4068-4071.
46. Starzyk J, Starzyk B, Bartnik-Mikuta A, Urbanowicz W, Dziatkowick H. Gonadotropin releasing hormone-independent precocious puberty in a 5 year-old girl with suprasellar germ cell tumor secreting beta-hCG and alpha-fetoprotein. J Pediatr Endocrinol Metab 2001; 14:789-796.
47. de Monleon JV, Simonin G, Pincemaille O, Buttin C, Sarles J. Precocious puberty secondary to an intramedullary germinoma. Arch Pediatr 1999; 6:46-49.
48. Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls wit the McCune-Albright syndrome. J Clin Endocrinol Metab 2003; 88:5730-5733.
49. Feuillan P, Merke D, Leschek, EW, Cutler GB Jr. Use of aromatase inhibitors in precocious puberty. Endocrinol Relat Cancer 1999; 6:303-306.
50. Bar A, Linder B, Sobel EH, Saenger P, DiMartino-Nardi J. Bayley-Pinneau method of height predication in girls with central precocious puberty: Correlation with adult height. J Pediatr 1995; 126:955-958.
51. Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr 1997; 86:808-815.
52. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs 2004; 6:211-213.
53. Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol (Oxf) 2002; 56:297-302.
54. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002; 109:E30.
55. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hormone determination two hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab 2004; 89:4338-4342.
56. Arrigo T, De Luca F, Antoniazzi F, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004; 150:533-537.
57. Palmert MR, Mansfield MJ, Crowley WF Jr., Crigler JF Jr., Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999; 84:4480-4488.
58. Muller J, Jull A, Andersson AM, Sehested A, Skakkebaek NE. Hormone changes during GnRH analogue therapy in children with central preococious puberty. J Pediatr Endocrinol Metab 2000; 13(Suppl 1):739-746.
59. Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab 1999; 84:449-452.
60. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following longacting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004; 61:626-634.
61. Baumann DA, Landolt MA, Wetterwald R, Dubuis JM, Sizonenko PC, Werder EA. Psychological evaluation of young women after medical treatment for central precocious puberty. Horm Res 2001; 56:45-50.
62. Couto-Silva AC, Adan L, Trivin C, Brauner R. Adult height in advanced puberty with or without gonadotropin hormone releasing hormone analog treatment. J Pediatr Endocrinol Metab 2002; 15:297-305.
63. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 2002; 58:1-7.
64. Tanaka T, Niimi H, Matsuo N, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: Evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese study group on central precocious puberty. J Clin Endocrinol Metab 2005; 90:1371-1376.
65. Carel JC, Roger M, Ispas S, et al. Final height after longterm treatment with tritorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999; 84:1973-1978.
66. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after longterm treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86:4711-4716.
67. van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Munick Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002; 87:506-512.
68. Antoniazzi F, Zamboni G, Bertoldo F, et al. Bone mass at final height in precocious puberty after gonadotropinreleasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003; 88:1096-1101.
69. Crofton PM, Evans NE, Wardhaugh B, Groome NP, Kelnar CJ. Evidence for increased ovarian follicular activity in girls with premature thelarche. Clin Endocrinol (Oxf) 2005; 62:205-209.
70. Freedman SM, Kreitzer PM, Elkowitz SS, Soberman N, Leonidas JC. Ovarian microcysts in girls with isolated premature thelarche. J Pediatr 1993; 122:246-249.
71. Pasquino AM, Pucarelli I, Passeri F, Segni M, Mancini MA, Municchi A. Progression of premature thelarche to central precocious puberty. J Pediatric 1995; 127:336-337.
72. Ghizzoni L, Milani S. The natural history of premature adrenarche. J Pediatr Endocrinol Metab 2000; 13(Suppl 5):1247-1251.
73. Siegel SF, Finegold DN, Urban MD, McVie R, Lee PA. Premature pubarche: Etiological heterogeneity. J Clin Endocrinol Metab 1992; 74:239-247.
74. Ibanez L, Potau N, Dunger D, de Zegher F. Precocious pubarche in girls and the development of androgen excess. J Pediatr Endocrinol Metab 2000; 13: 1261-1263.
75. Accetta SG, Di Domenico K, Ritter CG, Ritter AT, Capp E, Spritzer PM. Anthropometric and endocrine features in girls with isolated premature pubarche or non-classical congenital adrenal hyperplasia. J Pediatr 2004; 17: 767-773.
76. Patil KK, Ransley PG, McCullagh M, Malone M, Spitz L. Functioning adrenocortical neoplasms in children. BJU Int 2002; 89:562-565.
77. Street ME, Bandello MA, Terzi C, et al. Luteinizing hormone responses to leuprolide acetate discriminate between hypogonadotropic hypogonadism and constitutional delay of puberty. Fertil Steril 2002; 77:555-560.
78. Lee PA. Normal ages of pubertal events among American males and females. J Adolesc Health Care 1980; 1:26-29.
79. Sedlmeyer IL, Palmert MR. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab 2002; 87:1613-1620.
80. Reindollar RH, Byrd JR, McDonough PG. Delayed sexual development: a study of 252 patients. Am J Obstet Gynecol 1981; 140:371-380.
81. Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G. Spontaneous pubertal development in Turner’s syndrome. Italian Study Group for Turner’s Syndrome. J Clin Endocrinol Metab 1997; 82:1810-1813.
82. Myhre AG, Halonen M, Eskelin P, et al. Autoimmune polyendocrine syndrome type 1 (APS I) in Norway. Clin Endocrinol (Oxf) 2001; 54:211-217.
83. Layman LC, McDonough PG. Mutations of follicle stimulating hormone-beta and its receptor in human and mouse: genotype/phenotype. Mol Cell Endocrinol 2000; 161:9-17.
84. Meduri G, Touraine P, Beau I, et al. Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. J Clin Endocrinol Metab 2003; 88:3491-3498.
85. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000; 21:551-583.
86. Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981; 304:994-998.
87. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998; 27:927-943.
88. Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 2004; 25(1):90-92.
89. Sedlmeyer IL, Hirschhorn JN, Palmert MR. Pedigree analysis of constitutional delay of growth and maturation: determination of familial aggregation and inheritance patterns. J Clin Endocrinol Metab 2002; 87:5581-5586.
90. Seminara SB, Oliveira LM, Beranova M, Hayes FJ, Crowley WF Jr. Genetics of hypogonadotropic hypogonadism. J Endocrinol Invest 2000; 23:560-565.
91. Seminara SB, Achermann JC, Genel M, Jameson JL, Crowley WF Jr. X-linked adrenal hypoplasia congenita: a mutation in DAXI expands the phenotypic spectrum in males and females. J Clin EndocrMetab 1999; 84:4501-4509.
92. Kottler ML, Counis R, Bouchard P. Mutations of the GnRH receptor gene: a new cause of autosomal-recessive hypogonadotropic hypogonadism. Arch Med Res 1999; 30:481-485.
93. De Roux N, Genin E, Carel JC, Matsuda F, Chaussaun JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-dervied peptide receptor GPR54. Proc Natl Acad Sci U S A 2003; 16:10972-10976.
94. de Vries L, Lazar L, Phillip M. Craniopharyngioma: presentation and endocrine sequelae in 36 children. J Pediatr Endocrinol Metab 2003; 16:703-710.
95. Munoz MT, Argente J. Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances. Eur J Endocrinol 2002; 147:275-286.
96. Chern JP, Lin KH, Tsai WY, et al. Hypogonadotropic hypogonadism and hematologic phenotype in patients with transfusion-dependent beta-Thalassemia. J Pediatr Hematol Oncol 2003; 25:880-884.
97. Buchacz K, Rogol AD, Lindsey JC, et al. Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr 2003; 33:56-65.
98. Selevan SG, Rice DC, Hogan KA, et al. Blood lead concentration and delayed puberty in girls. N Engl J Med 2003; 348:1527-1536.
99. Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab 2001; 86:3039-3044.
100. Bertelloni S, Baroncelli GI, Ferdeghini M, Perri G, Maggese G. Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 1998; 83:4280-4283.
101. Albanese A, Stanhope R. Predictive factors at presentation in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 1995; 126:545-550.
102. Boas SR, Fulton JA, Koehler AN, Orenstein DM. Nutrition and pulmonary function predictors of delayed puberty in adolescent males with cystic fibrosis. Clin Pediatr 1998; 37:573-576.
103. Lee MM, Donahoe PK, Hasegawa T, et al. Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996; 81:571-576.
104. Martin MM, Martin AL. Constitutional delayed puberty in males and hypogonadotropic hypogonadism: a reliable and cost-effective approach to differential diagnosis. J Pediatr Endocrinol Metab 2005; 18:909-916.
105. Barrio R, de Luis D, Alonso M, Lamas A, Moreno JC. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril 1999; 71:244-248.
106. Zachmann M, Studer S, Prader A. Short-term testosterone treatment at bone age of 12 to 13 years does not reduce adult height in boys with constitutional delay of growth and adolescence. Helv Paediatr Acta 1987; 42:21-28.
107. Rensonnet C, Kanen F, Coremans C, Ernould C, Albert A, Bourguignon JP. Pubertal growth as a determinant of adult height in boys with constitutional delay of growth and puberty. Horm Res 1999; 51: 223-229.
108. Wickman S, Sipila I, Ankaberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomized controlled trial. Lancet 2001; 357:1743-1748.
109. Dunkel L, Wickman S. Novel treatment of short stature with aromatase inhibitors. J Steroid Biochem Mol Biol 2003; 86:345-356.
110. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:6396-6402.
111. Finkelstein JS, Klibanski A, Neer R. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 1996; 81:1152-1155.